A Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes.
A Randomized, Double-Blind, Placebo Controlled, Multicentre, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes. The ATLAS ACS TIMI 46 Study. 39039039-ACS-2001
Bayer Australia Limited
3,490 participants
Nov 17, 2006
Interventional
Conditions
Summary
The purpose of the study is to evaluate the safety of rivaroxaban in subjects with recent acute coronary syndrome and to assess the ability of rivaroxaban to reduce the rate of clinical events in those patients.
Eligibility
Inclusion Criteria1
- Have symptoms suggestive of ACS and a diagnosis of ST-elevation myocardial infarction or non-ST elevation myocardial infarction / unstable angina with at least 1 high risk feature. (ST is a section of the electrocardiograph wave.)
Exclusion Criteria1
- Active bleeding or high risk of bleeding or intracranial haemorrhage.Need for continued anticoagulant therapy.Significantly impaired renal or hepatic function.Severe concomitant diseases such as cardiogenic shock, refractory ventricular arrhythmias, or any severe condition that would limit life expectancy to less than 6 months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This study is designed to evaluate the safety and efficacy of rivaroxaban in subjects with recent Acute Coronary Syndrome who are receiving background low-dose aspirin therapy (75 to 100 mg/day) without the intention to use a thienopyridine therapy or with thienopyridine therapy. There will be 2 stages. Stage 1 will be for dose escalation while Stage 2 will be for dose confirmation. In Stage 1 there will be 3 total daily dose levels of rivaroxaban or placebo. 5 mg (2.5 mg twice a day or 5 mg once daily), 10 mg (5 mg twice a day or 10 mg daily) and 20 mg (10 mg twice a day or 20 mg daily). Mode of administration is oral. Two more additional dose levels may be added depending on the safety and efficacy profile observed in the first 3 dose levels. Maximum daily dose will not exceed 30 mg. All randomised subjects are planned to receive 6 months of treatment. In Stage 2, it is intended that a rivaroxaban once daily dose, twice daily dose or both will be selected for comparison to placebo. The dosage will be dependent upon the maximum tolerable dose for individual patient that was discovered during the dose escalation stage. Treatment will also be for 6 months.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000405415